Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

Mark S. Walker, Elaine Yu Pharm, Jiandong Kerr, Yeun Mi Yim, Edward J. Stepanski, Lee Schwartzberg

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC. Methods. Adult mCRC patients treated in the second-line setting with a regimen that included B, C, or chemotherapy only (O) and who had completed ≥ 1 Patient Care Monitor (PCM) surveys as part of routine clinical care were drawn from the ACORN Data Warehouse. Primary endpoints were rash, dry skin, itching, nail changes, nausea, vomiting, fatigue, burning in hands/feet, and diarrhea. Linear mixed models examined change in PCM scores across B, C and O (B = reference). Results: 182 patients were enrolled (B: n = 106, C: n = 38, O: n = 38). Patients were 51% female, 67% Caucasian, with mean age of 62.0 (SD = 12.6). Groups did not differ on demographic or clinical characteristics. The most common second-line regimens were FOLFIRI ± B or C (23.1%) and FOLFOX ± B or C (22.5%). Results showed baseline scores to be strongly predictive of second-line symptoms across all PCM items (all p's <.0001 except for Rash, p =.0013). Controlling for baseline, patients on B tended to have more stable and less severe symptoms. Patients on C had more severe rash, dry skin, and itching and had nail change scores that worsened faster than did B patients. Conclusions: Patients receiving second-line treatment for mCRC with B report less symptom burden, especially dermatologic, compared to patients treated with C.

Original languageEnglish (US)
Article number314
JournalBMC Research Notes
Volume5
DOIs
StatePublished - Jun 22 2012

Fingerprint

Nails
Colorectal Neoplasms
Skin
Quality of Life
Chemotherapy
Data warehouses
Fatigue of materials
Exanthema
Patient Care
Therapeutics
Pruritus
Nausea
Vomiting
Fatigue
Foot
Diarrhea
Linear Models
Hand
Demography
Cetuximab

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. / Walker, Mark S.; Pharm, Elaine Yu; Kerr, Jiandong; Yim, Yeun Mi; Stepanski, Edward J.; Schwartzberg, Lee.

In: BMC Research Notes, Vol. 5, 314, 22.06.2012.

Research output: Contribution to journalArticle

Walker, Mark S. ; Pharm, Elaine Yu ; Kerr, Jiandong ; Yim, Yeun Mi ; Stepanski, Edward J. ; Schwartzberg, Lee. / Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer. In: BMC Research Notes. 2012 ; Vol. 5.
@article{81cc5717acbe40d8a46c883a63ecc618,
title = "Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer",
abstract = "Background: Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC. Methods. Adult mCRC patients treated in the second-line setting with a regimen that included B, C, or chemotherapy only (O) and who had completed ≥ 1 Patient Care Monitor (PCM) surveys as part of routine clinical care were drawn from the ACORN Data Warehouse. Primary endpoints were rash, dry skin, itching, nail changes, nausea, vomiting, fatigue, burning in hands/feet, and diarrhea. Linear mixed models examined change in PCM scores across B, C and O (B = reference). Results: 182 patients were enrolled (B: n = 106, C: n = 38, O: n = 38). Patients were 51{\%} female, 67{\%} Caucasian, with mean age of 62.0 (SD = 12.6). Groups did not differ on demographic or clinical characteristics. The most common second-line regimens were FOLFIRI ± B or C (23.1{\%}) and FOLFOX ± B or C (22.5{\%}). Results showed baseline scores to be strongly predictive of second-line symptoms across all PCM items (all p's <.0001 except for Rash, p =.0013). Controlling for baseline, patients on B tended to have more stable and less severe symptoms. Patients on C had more severe rash, dry skin, and itching and had nail change scores that worsened faster than did B patients. Conclusions: Patients receiving second-line treatment for mCRC with B report less symptom burden, especially dermatologic, compared to patients treated with C.",
author = "Walker, {Mark S.} and Pharm, {Elaine Yu} and Jiandong Kerr and Yim, {Yeun Mi} and Stepanski, {Edward J.} and Lee Schwartzberg",
year = "2012",
month = "6",
day = "22",
doi = "10.1186/1756-0500-5-314",
language = "English (US)",
volume = "5",
journal = "BMC Research Notes",
issn = "1756-0500",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

AU - Walker, Mark S.

AU - Pharm, Elaine Yu

AU - Kerr, Jiandong

AU - Yim, Yeun Mi

AU - Stepanski, Edward J.

AU - Schwartzberg, Lee

PY - 2012/6/22

Y1 - 2012/6/22

N2 - Background: Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC. Methods. Adult mCRC patients treated in the second-line setting with a regimen that included B, C, or chemotherapy only (O) and who had completed ≥ 1 Patient Care Monitor (PCM) surveys as part of routine clinical care were drawn from the ACORN Data Warehouse. Primary endpoints were rash, dry skin, itching, nail changes, nausea, vomiting, fatigue, burning in hands/feet, and diarrhea. Linear mixed models examined change in PCM scores across B, C and O (B = reference). Results: 182 patients were enrolled (B: n = 106, C: n = 38, O: n = 38). Patients were 51% female, 67% Caucasian, with mean age of 62.0 (SD = 12.6). Groups did not differ on demographic or clinical characteristics. The most common second-line regimens were FOLFIRI ± B or C (23.1%) and FOLFOX ± B or C (22.5%). Results showed baseline scores to be strongly predictive of second-line symptoms across all PCM items (all p's <.0001 except for Rash, p =.0013). Controlling for baseline, patients on B tended to have more stable and less severe symptoms. Patients on C had more severe rash, dry skin, and itching and had nail change scores that worsened faster than did B patients. Conclusions: Patients receiving second-line treatment for mCRC with B report less symptom burden, especially dermatologic, compared to patients treated with C.

AB - Background: Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line treatment of mCRC. Methods. Adult mCRC patients treated in the second-line setting with a regimen that included B, C, or chemotherapy only (O) and who had completed ≥ 1 Patient Care Monitor (PCM) surveys as part of routine clinical care were drawn from the ACORN Data Warehouse. Primary endpoints were rash, dry skin, itching, nail changes, nausea, vomiting, fatigue, burning in hands/feet, and diarrhea. Linear mixed models examined change in PCM scores across B, C and O (B = reference). Results: 182 patients were enrolled (B: n = 106, C: n = 38, O: n = 38). Patients were 51% female, 67% Caucasian, with mean age of 62.0 (SD = 12.6). Groups did not differ on demographic or clinical characteristics. The most common second-line regimens were FOLFIRI ± B or C (23.1%) and FOLFOX ± B or C (22.5%). Results showed baseline scores to be strongly predictive of second-line symptoms across all PCM items (all p's <.0001 except for Rash, p =.0013). Controlling for baseline, patients on B tended to have more stable and less severe symptoms. Patients on C had more severe rash, dry skin, and itching and had nail change scores that worsened faster than did B patients. Conclusions: Patients receiving second-line treatment for mCRC with B report less symptom burden, especially dermatologic, compared to patients treated with C.

UR - http://www.scopus.com/inward/record.url?scp=84862305053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862305053&partnerID=8YFLogxK

U2 - 10.1186/1756-0500-5-314

DO - 10.1186/1756-0500-5-314

M3 - Article

VL - 5

JO - BMC Research Notes

JF - BMC Research Notes

SN - 1756-0500

M1 - 314

ER -